PHAT
Phathom Pharmaceuticals, Inc.15.24
+0.55+3.74%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.08BP/E (TTM)
-Basic EPS (TTM)
-3.76Dividend Yield
0%Recent Filings
8-K
VOQUEZNA trial data published
Phathom Pharmaceuticals announced on October 25, 2025, that additional analyses from its Phase 3 pHalcon-NERD-301 trial, evaluating VOQUEZNA tablets for Non-Erosive Reflux Disease, were published in the American Journal of Gastroenterology. The data showed VOQUEZNA 10 mg and 20 mg delivering 59.9% and 56.4% mean heartburn-free nights at week 4, versus 43.3% for placebo, with rapid onset after the first dose and sustained relief through 24 weeks. VOQUEZNA proved well tolerated, addressing the high burden of nighttime GERD symptoms affecting up to 80% of patients, where PPIs often fall short. Yet real-world efficacy may differ from trial results.
8-K
Phathom appoints new CFO
Phathom Pharmaceuticals appointed Sanjeev Narula as Chief Financial and Business Officer effective October 6, 2025, replacing Robert Breedlove as principal financial officer while Breedlove stays on as principal accounting officer. Narula, with deep finance experience from Intra-Cellular Therapies, Viatris, and Pfizer, starts with a $550,000 base salary and 50% target bonus. He receives stock options for 200,000 shares and 144,000 RSUs vesting over three to four years. This leadership shift bolsters financial oversight amid biopharma challenges.
10-Q
Q2 FY2025 results
Phathom Pharmaceuticals posted solid Q2 revenue of $39.5M, up sharply from $7.3M a year earlier and $28.5M sequentially (derived), driven by growing U.S. sales of VOQUEZNA products for GERD and H. pylori. Gross margin held steady at 87.2%, but operating expenses climbed to $94.4M from $83.2M y/y amid commercial ramp-up, yielding an operating loss of $59.9M versus $77.3M last year. Net loss narrowed to $75.8M from $91.4M, with EPS improving to -$1.05 from -$1.56 on 72.5M diluted shares—consistent with reported figures. Cash burn intensified, with operating cash flow at -$147.7M for H1 and ending cash at $149.6M, supporting operations through at least the next year; debt stands at $205.1M under the Hercules facility (9.85% rate, due Dec 2027) plus $347.0M revenue interest liability (9.26% effective rate). A May 2025 restructuring cut 6% of staff, trimming $8.0M in costs. Yet supply risks loom for clarithromycin in VOQUEZNA TRIPLE PAK.
8-K
Phathom Q2 revenues surge
Phathom Pharmaceuticals reported Q2 2025 net revenues of $39.5 million, up sharply from $7.3 million a year ago, fueled by 173,000 VOQUEZNA prescriptions—a 36% sequential jump. The company narrowed its net loss to $75.8 million while slashing costs through restructuring, targeting non-GAAP operating expenses under $60 million in Q3. FDA's 10-year exclusivity through 2032 shields the drug from generics until at least 2033. Full-year revenue guidance holds at $165 million to $175 million. Cash burn persists.
8-K
FDA confirms VOQUEZNA exclusivity
Phathom Pharmaceuticals announced on June 16, 2025, that the FDA corrected the Orange Book to confirm VOQUEZNA's full 10-year NCE exclusivity through May 3, 2032. This update aligns with statutory rules, bolstering the drug's protected commercial path. Exclusivity secures the runway. Yet risks like competition or commercialization hurdles persist, as noted in SEC filings.
IPO
Employees
Sector
Industry
GOSS
Gossamer Bio, Inc.
3.56-0.23
HEPA
Hepion Pharmaceuticals, Inc.
0.07-0.01
LSTA
Lisata Therapeutics, Inc.
2.05+0.01
MIRM
Mirum Pharmaceuticals, Inc.
67.05+2.95
PHGE
BiomX Inc.
1.55-0.18
PHIO
Phio Pharmaceuticals Corp.
1.08-0.01
PHVS
Pharvaris N.V.
24.72+0.82
PMVP
PMV Pharmaceuticals, Inc.
1.18-0.02
VNDA
Vanda Pharmaceuticals Inc.
6.65+0.02
VRNA
Verona Pharma plc
106.91+0.00